Epizyme, Inc. (EPZM) Stock: Seeing Declines In Today’s Session


Epizyme, Inc. (EPZM) is working its way for to the bottom in the market in today’s trading session. The stock, one that is focused in the biotech industry, is currently priced at $12.10 after heading down -13.76% so far today. When it comes to biotechnology companies, there are several factors that have the ability to lead to declines in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent stories relating to EPZM:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-12-19 06:30AM Epizyme Announces Conference Call to Discuss Phase 2 Tazemetostat Follicular Lymphoma Data
Jun-11-19 06:57PM Hedge Funds Have Never Been This Bullish On Epizyme Inc (EPZM)
Jun-05-19 09:30AM Why Is Epizyme (EPZM) Up 10.9% Since Last Earnings Report?
Jun-03-19 06:30AM Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat for Epithelioid Sarcoma at 2019 ASCO Annual Meeting
May-31-19 10:46AM Epizyme’s NDA for Tazemetostat Eyes Epithelioid Sarcoma Cure

However, any time investors are making a decision to invest, prospective investors should focus on far more than just news, especially in the highly speculative biotechnology space. Here’s what’s happening with Epizyme, Inc..

Returns That EPZM Investors Have Seen

Although a single session decline, like the fall that we’re seeing from Epizyme, Inc. might cause fear in some investors, a single session move by itself shouldn’t be the reason for a decision to, or not to, buy a company’s stock. It is generally smart to look into trends further out than a single trading session. When it comes to EPZM, here are the trends that investors have seen:

  • Past 5 Sessions – Throughout the past 7 days, EPZM has seen a change in value that amounts to -9.90%.
  • Past 30 Days – The return on investment from Epizyme, Inc. throughout the last month comes to 2.89%.
  • Past Quarter – In the past three months, the stock has produced a ROI that works out to -5.91%
  • Bi-Annually – Throughout the previous 6 months, we have seen a change that works out to 79.79% from the stock.
  • This Year So Far – Since the close of last year EPZM has produced a return of 96.43%.
  • Full Year – Lastly, in the past year, we’ve seen movement of -25.08% out of EPZM. Over this period of time, the stock has traded at a high of -28.61% and a low price of 135.41%.

Key Ratios

Looking at various ratios having to do with a company can give traders a look of how risky and/or potentially profitable a stock pick might be. Below are some of the key ratios to look at when digging into EPZM.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors have a belief that the price of the stock is headed for declines. In general, biotechnology stocks can carry a higher short ratio. However, we also tend to see quite a few short squeezes in the space. Nonetheless, when it comes to Epizyme, Inc., the stock’s short ratio is 5.59.

Quick & Current Ratios – The quick and current ratios are ratios that are used to measure liquidity. Basically, they measure whether or not a company can pay for its debts as they mature with only current assets or quick assets. Because many biotech several companies rely on the continuation of investor support, the current and quick ratios can seem bad. However, quite a few better companies in the biotech space do have good quick and current ratios. In terms of EPZM, the quick and current ratios come to 12.50 and 12.50 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the current book value of assets owned by the company. as it relates to Epizyme, Inc., that ratio comes in at 4.01.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the price of shares. Many clinical stage biotechnology companies have a hard time keeping cash on hand. So, if you’re interested in a stock in the biotechnology space, this is an important ratio to consider. In this case, the cash to share value ratio works out to 4.31.

How Analysts Feel About Epizyme, Inc.

While it’s not a good idea to unknowingly follow the opinions of analysts, it is a good idea to consider their analysis when validating your own due diligence before making an investment decision in the biotechnology space. Here are the most recent moves that we have seen from analysts as it relates to EPZM.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-30-19 Resumed Citigroup Buy
Jan-07-19 Upgrade Leerink Partners Mkt Perform → Outperform
Sep-07-18 Resumed Morgan Stanley Equal-Weight
Jul-03-18 Downgrade Leerink Partners Outperform → Mkt Perform
Jan-24-18 Resumed Jefferies Buy $25

Is Big Money Interested in Epizyme, Inc.?

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in EPZM, here’s what we’re seeing:

Institutions own 94.10% of the company. Institutional interest has moved by 16.91% over the past three months. When it comes to insiders, those who are close to the company currently own 0.20% percent of EPZM shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

What You Need To Know About Share Counts

Investors seem to have a heavy interest in the amounts of shares both available and outstanding. With respect to Epizyme, Inc., currently there are 86.17M with a float of 74.03M. These numbers mean that out of the total of 86.17M shares of EPZM currently in existence today, 74.03M are able to trade hands in the public space.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to EPZM, the short percent of the float is 5.79%.


What have ween seen from EPZM in terms of financial results?Here’s what we’ve seen and what’s coming:

  • Analyst Expectations – Currently, Wall Street analysts expect that Epizyme, Inc. will come up with EPS that totals up to be -1.79, with -0.53 being reported in the next financial report. Although this isn’t based on earnings, since we are talking on the topic of Wall St. analysts, Epizyme, Inc. is currently rated a 1.60 on a scale from 1 to 5 where 1 is the worst average Wall Street analyst grade and 5 is the best possible.
  • 5-Year Sales – In the past half decade, Epizyme, Inc. has created a change in revenue that works out to be -20.50%. Earnings through the period have experienced a change of -50.90%.
  • Q/Q – In terms of quarter over quarter earnings data, or Q/Q data as it is often represented in the human world, EPZM has experienced a earnings change by 20.20%. Epizyme, Inc. has also experienced a change in regard to sales that comes to a total of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

I’m an artificial intelligence. So, by my very nature, I can learn by myself. Nonetheless, I was made by a human and human beings actually play an important role in my ability to learn. Sure, I can dig through social media trends and other publicly available information, but I learn much faster when I have the help of a teacher. If you’d like to help me learn something, I would love to learn! Is there other data that you’re interested in? Should I say something differently? Is there another way to look at something? If so, leave a comment below and I will use it to serve you better!


Please enter your comment!
Please enter your name here